Delivery Order SPE2DB22D9239-SPE2DB26FDD84
- Not listed
- The Defense Logistics Agency awarded a $10,042.02 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 250 microgram vials of Nplate. The delivery order, issued May 12, 2025, with completion targeted for June 3, 2025, carries no set-aside designation. DMS Pharmaceutical Group leverages its position as a woman-owned small business to compete in federal procurement while fulfilling this...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nplate 250 microgram vials. This $1,673.67 firm fixed-price delivery order was issued on July 24, 2025, with an ultimate completion date of August 14, 2025. The contract utilizes no set-aside designation and is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under...
- The Defense Logistics Agency awarded a delivery order valued at $1,673.67 to DMS Pharmaceutical Group Inc. for the supply of Nplate 250 microgram vials. This firm fixed-price delivery order, issued on August 8, 2025, with an ultimate completion date of August 29, 2025, represents a pharmaceutical supply requirement to support Department of Defense healthcare operations. The award was made without a set-aside designation, and the products will be delivered to Park Ridge, Illinois, where the...
- The Defense Logistics Agency awarded a $6,657.68 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on September 26, 2025, for the supply of Nplate 500 micrograms vials. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA valued at $500 million through November 2026, which authorizes the agency to procure a comprehensive range of pharmaceutical products supporting military healthcare facilities worldwide. The contract...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc. on September 16, 2025, for the supply of Nplate 500 microgram vials, with a ceiling value of $20,091.18. This firm fixed-price delivery order is set to conclude by October 7, 2025, and represents a discrete pharmaceutical product delivery under DMS Pharmaceutical Group's larger indefinite delivery contract with DLA. The contract involves no set-aside designation, and fulfillment will occur at the vendor's...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $6,697.06 by the Defense Logistics Agency (DLA) on August 25, 2025, for the supply of Nplate 500 microgram vials. This firm fixed-price delivery order is part of DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $500 million vehicle valid through November 2026 that enables the agency to...
- The Defense Logistics Agency awarded a delivery order valued at $6,697.06 to DMS Pharmaceutical Group Inc. for the supply of Nplate 500 microgram vials. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform work at its Park Ridge facility with an ultimate completion date of August 14, 2025. This delivery order utilizes a firm fixed-price contract type with no set-aside designation, allowing the company to compete on a...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $16,736.70 by the Defense Logistics Agency on October 20, 2025, for the supply of Nplate 250 mcg vials. This firm fixed-price delivery order, with an ultimate completion date of November 10, 2025, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is...
- The Defense Logistics Agency awarded a $6,697.06 delivery order to DMS Pharmaceutical Group Inc. on July 28, 2025, for the supply of Nplate 500 microgram vials, with an ultimate completion date of August 18, 2025. This firm fixed-price delivery order was issued without a set-aside designation and represents a pharmaceutical supply fulfillment for federal healthcare needs. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, serves...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,394.12 to DMS Pharmaceutical Group Inc. for 500 microgram vials of Nplate on September 24, 2025. This firm fixed-price delivery order, which must be completed by October 16, 2025, was issued without a set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its facility in Park Ridge. Nplate is a prescription...
- SPE2DB22D9239Indefinite Delivery Contract
- SPE2DB22D9239-SPE2DB26FDD84Delivery Order
The Defense Logistics Agency awarded a $25,111 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Nplate 500 microgram vials. This firm fixed-price delivery order was issued on October 29, 2025, with an ultimate completion date of November 20, 2025, and requires performance at the contractor's Park Ridge facility. The award carries no set-aside designation, indicating the contractor competed in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. That parent contract, awarded on November 13, 2025, carries a $500 million ceiling value and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy. The PPV-G GEN V program enables the Defense Logistics Agency to issue delivery orders for comprehensive pharmaceutical products and medical consumables to support recurring medical supply needs of military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance across multiple delivery orders demonstrates its capability to fulfill the diverse pharmaceutical requirements of Department of Defense healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.1k | 10/29/25 |